Pfizer Inc. announced that the US Federal Trade Commission has terminated the waiting period for Pfizer's pending acquisition of Wyeth, while the Canadian Competition Bureau has approved the deal.

China, Australia and the EU have also approved of the acquisition.

With the receipt of these clearances, Pfizer has now satisfied the regulatory approval requirements under the merger agreement to complete the acquisition of Wyeth.

Pfizer expects to close the transaction on October 15, 2009.

The Federal Trade Commission's and Canadian Competition Bureau's decisions require Pfizer to divest certain animal health assets in the US and Canada, respectively, to Boehringer Ingelheim, as previously announced.

In addition, the Canadian Competition Bureau's decision includes Pfizer's commitment to amend an existing distribution agreement in Canada related to Estring.